We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bioo Scientific Launches Transduction Reagents for Targeted Delivery into Neuronal and Myeloid Cells
Product News

Bioo Scientific Launches Transduction Reagents for Targeted Delivery into Neuronal and Myeloid Cells

Bioo Scientific Launches Transduction Reagents for Targeted Delivery into Neuronal and Myeloid Cells
Product News

Bioo Scientific Launches Transduction Reagents for Targeted Delivery into Neuronal and Myeloid Cells


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Bioo Scientific Launches Transduction Reagents for Targeted Delivery into Neuronal and Myeloid Cells"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Reagents offer directed delivery of RNAi agents into myeloid cells (both in primary cells and in cell lines) or into neuronal cells (both in primary cells and in cell lines) respectfully.

These transduction reagents are able to transduce siRNA to targeted cells both in vitro and in vivo

NeuroAim-and-MyeloAim-pictu.gif
resulting in efficient gene silencing in cells of human, mouse, and rat origin. The MyeloAim™ and NeuroAim™ Transduction Reagents provide a safe and noninvasive approach for the delivery of siRNA and potentially other therapeutic molecules to these cells.

According to Dr. Sandesh Subramanya, Senior Scientist at Bioo Scientific, “The NeuroAim and MyeloAim transduction reagents are the only delivery vehicles available in the market for cell-specific delivery of siRNA and miRNA. These are valuable tools for researchers that focus on studies that require delivering therapeutic small RNAs to neuronal cells and myeloid cells. A huge advantage here is that all payload can ‘selectively hit the mark’ by minimizing targeting to non-specific tissues and cells, be well tolerated, and provide a high therapeutic index.”

Advertisement